Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

Completed

• Conditions: Age Related Macular Degeneration; Central Serous Chorioretinopathy; Choroidal Neovascularization

• Registration Number: NCT01880788
• Lead Sponsor: Sequenom, Inc.

Brief Summary

The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.

Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.

Detailed Description

To determine if patients presenting with type 1 neovascularization believed to be secondary to CSC are genetically distinct from typical CSC patients without neovascularization or patients presenting with choroidal neovascularization (CNV) secondary to advanced AMD. Disease associated markers detecting variants in ARMS 2, Complement Factor H (CFH) Complement component 3 (C3), Complement component 2 (C2) , Factor B (FB), VEGFA or other genetic polymorphisms associated with CNV will be evaluated to determine if the CSC neovascular group is genetically distinct from the CSC group without neovascularization or the advanced AMD group.

Study Timeline

• Study Start: 2012-11
• Study First Submitted: 2013-05-16
• Study First Submitted QC: 2013-06-18
• Study First Posted: 2013-06-19
• Primary Completion: 2015-03
• Study Completion: 2015-08
• Status Verified: 2015-09
• Last Update Submitted: 2015-09-17
• Last Update Posted: 2015-09-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 152

Inclusion Criteria

• Caucasian
• 30 years and older (CSC)
• 50 years and older (Advanced AMD)
• Genders Eligible for Study: Both
• Completed Consent form
• Diagnosis of choroidal neovascularization in at least one eye

Exclusion Criteria

• Patient age less than 30 years (CSC).
• Patient age less than 50 years (AMD).
• Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD and CSC such as high myopia, retinal dystrophies, retinal vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which have been present prior to the age of 30.
• Opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate fundus photography.
• Missing informed consent
• Previous sample donation under this protocol

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Total genetic burden	Baseline assessment	The identification of individual genetic markers or a quantitative measure of total genetic burden associated with CNV secondary to CSC vs. CSC vs. CNV secondary to advanced AMD as meaured by the commercially available RetnaGene AMD assay.

Trial Locations

Locations (1)

Vitreous Retina Macula Consultants of New York; 🇺🇸 New York City, New York, United States